<DOC>
	<DOCNO>NCT03106428</DOCNO>
	<brief_summary>To assess safety tolerability , describe dose-limiting toxicity , determine maximum tolerate dose ( MTD ) high protocol-defined dose ( maximum administer dose ) absence establish MTD , recommend dose evaluation MEDI7247 patient select hematological malignancy relapse , refractory prior standard therapy , standard salvage regimen available .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study MEDI7247 Patients With Selected Relapsed/Refractory Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Age ≥ 18 year time screen . 2 . Written inform consent locally require authorization 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 4 . Female patient childbearing potential sexually active nonsterilized male partner must use least one highly effective method contraception 7 day postscreening , must agree continue use precaution 90 day last dose investigational product . 5 . Nonsterilized male patient sexually active female partner childbearing potential must use male condom plus spermicide 7 day postscreening 90 day receipt last dose investigational product . 1 . Received cytotoxic chemotherapy within 21 day ( 42 day nitrosureas mitomycin C ) prior first schedule dose MEDI7247 . 2 . Received major surgery ( define Investigator ) , radiotherapy , immunotherapy within 28 day first schedule dose MEDI7247 . 3 . Received investigational drug within 14 day 5 halflives , whichever short , first schedule dose MEDI7247 recover associated toxicity . 4 . Patients previously receive autologous SCT , exclude less 90 day elapse time transplant patient recover transplantassociated toxicity prior first schedule dose MEDI7247 . 5 . Failure recover prior treatmentrelated nonhematological toxicity ≤ Grade 1 prior first schedule dose MEDI7247 ( except alopecia neuropathy ) . 6 . Patients risk nondisease related major bleeding ( eg , recent GI hemorrhage neurosurgery , within previous 21 day ) . 7 . Central nervous system ( CNS ) disease untreated , symptomatic , require therapy control symptom . 8 . Active human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection time screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>